Outcome of Board Meeting
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved audited financial results for Q4 and FY2026 (ended March 31, 2026). The Board recommended a final dividend of Rs. 0.50 per share (10% on Rs. 5 face value), with July 3, 2026 as record date. Statutory auditors changed from B S R & Co. LLP to S.R. Batliboi & Associates LLP for a 5-year term from the 48th AGM. Six new directors are being appointed including Mr. Rajiv Malik, Mr. Daniel Bradbury, and Dr. Peter Piot, effective August 1, 2026. The Company approved acquiring the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) through issuance of 87.92 lakh equity shares at Rs. 376.16 per share (Rs. 330.73 crore total), converting OCDs and CCDs into BBL equity, taking ownership to ~99.99%. A new Long-Term Incentive Plan was also approved.
The acquisition of remaining BBL stake will make it a near-wholly-owned subsidiary, simplifying corporate structure and enabling unified strategy. Change in auditors and appointment of multiple new independent directors with global pharma backgrounds signals board strengthening. Share swap will dilute existing shareholders by ~87.9 lakh shares.